CytoMed Therapeutics (GDTC) Current Deferred Revenue (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Current Deferred Revenue of $138724.3 for Q4 2025, up 74.94% sequentially from $79299.0 in Q2 2025, and up 71.27% YoY from $80997.9 in Q4 2024.
CytoMed Therapeutics (GDTC) Current Deferred Revenue (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $138724.3 in Q4 2025.
- Quarterly Current Deferred Revenue rose 71.27% year-over-year to $138724.3 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138724.3 (up 71.27% YoY) and the FY2025 annual result came in at $139819.0, up 73.35% from the prior year.
- Current Deferred Revenue advanced to $138724.3 in Q4 2025 per GDTC's latest filing, from $79299.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $138724.3 in Q4 2025 and troughed at $2524.8 in Q4 2022.
- A 5-year average of $40668.8 and a median of $7723.1 in 2021 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue sank 74.6% in 2022, then jumped 1904.29% in 2024.
- Over 5 years, Current Deferred Revenue stood at $9942.1 in 2021, then tumbled by 74.6% to $2524.8 in 2022, then surged by 60.06% to $4041.2 in 2023, then surged by 1904.29% to $80997.9 in 2024, then soared by 71.27% to $138724.3 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $138724.3, $79299.0, and $80997.9 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,724.32 |
| Jun 30, 2025 | 79,299.00 |
| Dec 31, 2024 | 80,997.90 |
| Jun 30, 2024 | 4,317.00 |
| Dec 31, 2023 | 4,041.22 |
| Jun 30, 2023 | 5,504.00 |
| Dec 31, 2022 | 2,524.85 |
| Dec 31, 2021 | 9,942.11 |